TECH
Overvalued by 52.7% based on the discounted cash flow analysis.
Market cap | $13.05 Billion |
---|---|
Enterprise Value | $13.30 Billion |
Dividend Yield | $0.3189 (0.38%) |
Earnings per Share | $1.26 |
Beta | 1.06 |
Outstanding Shares | 157,584,637 |
Avg 30 Day Volume | 1,284,426 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 64.32 |
---|---|
PEG | -213.5 |
Price to Sales | 11.97 |
Price to Book Ratio | 6.98 |
Enterprise Value to Revenue | 11.52 |
Enterprise Value to EBIT | 53.56 |
Enterprise Value to Net Income | 65 |
Total Debt to Enterprise | 0.03 |
Debt to Equity | 0.19 |
No data
No data
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems , No...